SEC Form SC 13G filed by Phibro Animal Health Corporation
$PAHC
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/7/2025 | $35.00 | Neutral → Overweight | Analyst |
| 6/16/2025 | $24.00 | Underperform → Neutral | BNP Paribas Exane |
| 9/10/2024 | $22.00 | Neutral | JP Morgan |
| 12/7/2023 | $9.00 | Underperform | Exane BNP Paribas |
| 12/21/2022 | $18.00 | Buy | ROTH Capital |
| 7/25/2022 | $22.00 | Equal Weight → Underweight | Barclays |
| 1/10/2022 | $23.00 | Underweight → Equal-Weight | Barclays |
| 11/18/2021 | $23.00 | Equal-Weight | Morgan Stanley |
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
10-Q - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 17, 2025, to stockholders of record at the close of business on November 26, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please vis
Phibro Animal Health Corporation is proud to announce the national launch of Restoris™ piezoelectric dental gel, a revolutionary dental gel designed to treat and support long-term oral health in dogs with periodontal disease. Developed in collaboration with a leading U.S. dental school and licensed to Phibro, Restoris represents a breakthrough in veterinary dental care, offering a dual mechanism of action to restore oral health at its foundation. The launch of Restoris builds on our recently announced license agreement for a novel therapeutic product targeting periodontal health in companion animals through a different mechanism of action. Together, these products form the foundation of a
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its first quarter financial results on Wednesday, November 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 6, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To a
Analyst upgraded Phibro Animal Health from Neutral to Overweight and set a new price target of $35.00
BNP Paribas Exane upgraded Phibro Animal Health from Underperform to Neutral and set a new price target of $24.00
JP Morgan initiated coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $22.00
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Joyce J. Lee, MBA, as a Class II director of the Company, effective immediately. Ms. Lee will be an independent director. Her appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Ms. Lee brings a wealth of expertise and leadership to our Board of Directors, most recently serving as President of Cobb Vantress LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Before joining Cobb Vantress, Ms. Lee held executive positions at Elanco, Bayer Animal Health, and Zoetis.
Damian Finio to Succeed Javier Daly as Chief Financial Officer TRENTON, N.J., Sept. 6, 2023 /PRNewswire/ -- TerraCycle Inc., the international leader in innovative sustainability solutions, today announced Damian Finio will join the company's global leadership team as Chief Financial Officer, effective October 2. Finio most recently served as Chief Financial Officer of Phibro Animal Health Corporation (NASDAQ:PAHC) and joins TerraCycle with more than 30 years of financial management experience, primarily in the life sciences industry having spent nearly half of his career at
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately. Mr. Bernal will be an independent director. His appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Mr. Bernal recently became Chief Executive Officer of PetDx® – The Liquid Biopsy Company for Pets™, a company based in San Diego, CA, and focused on early detection of cancer using Next Generation Sequencing (NGS) technology. Prior to joining PetDx, Mr. Bernal was the President for Mars Veterinary Health International and
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 17, 2025, to stockholders of record at the close of business on November 26, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please vis
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its first quarter financial results on Wednesday, November 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 6, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To a
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026. Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024) Net sales of $378.7 million, an increase of $105.5 million, or 39% Net income of $17.2 million, an increase of $16.5 million Diluted earnings per share of $0.42, an increase of $0.40 Adjusted EBITDA of $50.0 million, an increase of $16.5 million, or 49% Adjusted net income of $23.2 million, an increase of $6.6 million, or 39% Adjusted
SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)